0.83
price up icon0.30%   0.0025
after-market Handel nachbörslich: .81 -0.02 -2.41%
loading

Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten

pulisher
Nov 01, 2024

Adaptimmune faces Nasdaq delisting over share price - Investing.com India

Nov 01, 2024
pulisher
Oct 17, 2024

NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register

Oct 17, 2024
pulisher
Oct 16, 2024

Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024
pulisher
Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024
pulisher
Oct 10, 2024

Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle

Oct 09, 2024
pulisher
Oct 08, 2024

Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 04, 2024
pulisher
Oct 02, 2024

Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News

Oct 02, 2024
pulisher
Oct 02, 2024

Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily

Oct 02, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com

Sep 27, 2024
pulisher
Sep 25, 2024

Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily

Sep 25, 2024
pulisher
Sep 24, 2024

Adaptimmune finalizes settlement with Genentech - Investing.com India

Sep 24, 2024
pulisher
Sep 23, 2024

ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex

Sep 23, 2024
pulisher
Sep 20, 2024

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK

Sep 20, 2024
pulisher
Sep 20, 2024

Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle

Sep 20, 2024
pulisher
Sep 18, 2024

Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Zumiez Inc’s latest rating changes from various analysts - Knox Daily

Sep 18, 2024
pulisher
Sep 17, 2024

AdaptHealth Stock Earns RS Rating Upgrade - MSN

Sep 17, 2024
pulisher
Sep 17, 2024

A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News

Sep 17, 2024
pulisher
Sep 16, 2024

Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News

Sep 16, 2024
pulisher
Sep 13, 2024

Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily

Sep 13, 2024
pulisher
Sep 10, 2024

There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News

Sep 10, 2024
pulisher
Sep 09, 2024

Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex

Sep 09, 2024
pulisher
Sep 09, 2024

Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News

Sep 09, 2024
pulisher
Sep 06, 2024

A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily

Sep 06, 2024
pulisher
Sep 06, 2024

EWCZ Shares Experience Decline in Value - Knox Daily

Sep 06, 2024
pulisher
Sep 06, 2024

Natera Inc [NTRA] Shares Jump Approximately 97.71% Over the Year - Knox Daily

Sep 06, 2024
pulisher
Sep 06, 2024

Adaptimmune Therapeutics Plc ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Sep 06, 2024
pulisher
Sep 06, 2024

Premier Inc [PINC] Shares Fall -1.35 % on Thursday - Knox Daily

Sep 06, 2024
pulisher
Sep 05, 2024

An analyst sees good growth prospects for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Sep 05, 2024
pulisher
Sep 05, 2024

Closing Figures: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.16, Down -4.13 - The Dwinnex

Sep 05, 2024
pulisher
Aug 28, 2024

Analyzing Adaptimmune Therapeutics Plc ADR (ADAP) After Recent Trading Activity - Knox Daily

Aug 28, 2024
pulisher
Aug 28, 2024

Adaptimmune Therapeutics Plc ADR (ADAP) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Aug 28, 2024
pulisher
Aug 28, 2024

Market Recap Check: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.24, Up/Down -6.77 - The Dwinnex

Aug 28, 2024
pulisher
Aug 27, 2024

Adaptimmune Therapeutics Plc ADR: Rising -35.12% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Aug 27, 2024
pulisher
Aug 26, 2024

A closer look at Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price trends - US Post News

Aug 26, 2024
pulisher
Aug 22, 2024

Adaptimmune Therapeutics Plc ADR (ADAP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

Aug 22, 2024
pulisher
Aug 21, 2024

A better buy-in window may exist right now for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Aug 21, 2024
pulisher
Aug 20, 2024

Financial Analysis: Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratios Unveil Key Insights - The Dwinnex

Aug 20, 2024
pulisher
Aug 19, 2024

The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - US Post News

Aug 19, 2024
pulisher
Aug 14, 2024

It is Poised to be a Bull Market for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Aug 14, 2024
pulisher
Aug 13, 2024

Earnings call: Adaptimmune announces Tecelra launch and solid Q2 results - Investing.com India

Aug 13, 2024
pulisher
Aug 12, 2024

Adaptimmune Therapeutics Plc ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle

Aug 12, 2024
pulisher
Aug 12, 2024

Stock Performance Spotlight: Adaptimmune Therapeutics Plc ADR (ADAP) Ends the Day at 0.99, Up by 0.56 - The Dwinnex

Aug 12, 2024
pulisher
Aug 12, 2024

Can you now get a good deal on Adaptimmune Therapeutics Plc ADR’s shares? - US Post News

Aug 12, 2024
pulisher
Aug 09, 2024

ADAP Stock Sees Decline of Approximately -22.28% in Last Five Days - Knox Daily

Aug 09, 2024
pulisher
Aug 07, 2024

Are Smart Investors Making the Right Decision? Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Aug 07, 2024
pulisher
Aug 05, 2024

Market cap of Adaptimmune Therapeutics Plc ADR [ADAP] reaches 298.93M – now what? - The DBT News

Aug 05, 2024
pulisher
Aug 05, 2024

Investor’s Delight: Adaptimmune Therapeutics Plc ADR (ADAP) Closes Weak at 1.17, Down -7.87 - The Dwinnex

Aug 05, 2024
pulisher
Aug 02, 2024

FDA grants accelerated approval for new sarcoma cell therapy - Investing.com India

Aug 02, 2024
pulisher
Aug 01, 2024

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor - Quantisnow

Aug 01, 2024
pulisher
Jul 31, 2024

Taking on analysts’ expectations and winning: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Jul 31, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):